---
document_datetime: 2025-08-13 10:27:37
document_pages: 7
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/chenodeoxycholic-acid-leadiant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: chenodeoxycholic-acid-leadiant-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 4.6637196
conversion_datetime: 2025-12-31 01:48:36.88353
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
<!-- image -->

## Chenodeoxycholic acid Leadiant

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                                                                | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                                    |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------|
| PSUSA/10590 /202410  | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only) | 22/05/2025                          | 23/07/2025                                  | SmPC and PL                      | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/10590/202410. |
| IA/0026/G            | This was an application for a group of variations. B.III.1.b.3 - Submission of a new/updated or                                                                      | 26/11/2024                          | n/a                                         |                                  |                                                                                                                                            |

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                     | deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer   |            |     |                                                                                                                                                                                                                                                                                                                             |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0025             | B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer                                                                                                                   | 26/11/2024 | n/a |                                                                                                                                                                                                                                                                                                                             |
| S/0024              | 7th annual re-assessment.                                                                                                                                                                                                                                                      | 25/07/2024 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Chenodeoxycholic acid Leadiant should be maintained.                                     |
| PSUSA/10590 /202310 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only)                                                                                                           | 16/05/2024 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                           |
| S/0022              | 6th annual re-assessment                                                                                                                                                                                                                                                       | 20/07/2023 | n/a | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that the marketing authorisation under exceptional circumstances of Chenodeoxycholic acid Leadiant should be maintained. |
| PSUSA/10590 /202210 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile                                                                                                                                                                              | 12/05/2023 | n/a | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                           |

<div style=\"page-break-after: always\"></div>

|                     | acid synthesis, xanthomatosi - centrally authorised products only)                                                                                                   |            |            |                                  |                                                                                                                                                                                                                                                                                                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0020              | 5th annual re-assessment                                                                                                                                             | 21/07/2022 | n/a        |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Chenodeoxycholic acid Leadiant should be maintained.                                 |
| PSUSA/10590 /202110 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only) | 05/05/2022 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                       |
| R/0018              | Renewal of the marketing authorisation.                                                                                                                              | 14/10/2021 | 09/12/2021 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Chenodeoxycholic acid Leadiant in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity.                            |
| S/0017              | 4th annual re-assessment.                                                                                                                                            | 14/10/2021 | n/a        |                                  | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation under exceptional circumstances of Chenodeoxycholic acid Leadiant should be maintained. |
| PSUSA/10590 /202010 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only) | 06/05/2021 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                       |

<div style=\"page-break-after: always\"></div>

| IB/0015/G           | This was an application for a group of variations.                                                                                                                   | 06/01/2021   | n/a        |                   |                                                                                                                                                                                                                                                                                                                         |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0014              | 3rd annual re-assessment                                                                                                                                             | 23/07/2020   | n/a        |                   | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation under exceptional circumstances of Chenodeoxycholic acid Leadiant should be maintained. |
| PSUSA/10590 /201910 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only) | 17/04/2020   | n/a        |                   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                       |
| IB/0012             | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                        | 08/01/2020   | 17/12/2020 | SmPC and Annex II |                                                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

| PSUSA/10590 /201904   | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised                                                                                                                                                                                                                                                            | 31/10/2019   | n/a   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                       |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| S/0010                | 2nd annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                        | 17/10/2019   | n/a   | The CHMP, having reviewed the evidence of compliance with the specific obligations and the impact of the data submitted by the MAH on the benefit/risk profile of the medicinal product, concluded that marketing authorisation of Chenodeoxycholic acid Leadiant should be maintained. |
| PSUSA/10590 /201810   | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only)                                                                                                                                                                                                                                             | 16/05/2019   | n/a   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                       |
| PSUSA/10590 /201804   | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only)                                                                                                                                                                                                                                             | 31/10/2018   | n/a   | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                       |
| IA/0008/G             | This was an application for a group of variations. B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting | 29/08/2018   | n/a   |                                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|                     | material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.2 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - New certificate for a starting material/reagent/intermediate/or excipient from a new or an already approved manufacturer B.III.1.b.3 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Updated certificate from an already approved manufacturer B.III.1.b.4 - Submission of a new/updated or deletion of Ph. Eur. TSE Certificate of Suitability - Deletion of certificates (in case multiple certificates   |            |            |      |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|-----------------------------------|
| S/0006              | Annual re-assessment.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       | 26/07/2018 | n/a        |      |                                   |
| PSUSA/10590 /201710 | Periodic Safety Update EU Single assessment - chenodeoxycholic acid (inborn error in primary bile acid synthesis, xanthomatosi - centrally authorised products only)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        | 17/05/2018 | n/a        |      | PRAC Recommendation - maintenance |
| IB/0004             | B.II.f.1.b.1 - Stability of FP - Extension of the shelf life of the finished product - As packaged for sale (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 28/09/2017 | 31/05/2018 | SmPC |                                   |

<div style=\"page-break-after: always\"></div>

| IB/0003/G   | a group of variations. A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                          | 04/07/2017   | 31/05/2018   | Annex II and PL                  | This was an application for   |
|-------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|----------------------------------|-------------------------------|
| T/0001      | Transfer of Marketing Authorisation                                                                                                                                                                                                                                                                                                                                      | 12/05/2017   | 31/05/2017   | SmPC, Labelling and PL           |                               |
| IB/0002/G   | This was an application for a group of variations. A.2.a - Administrative change - Change in the (invented) name of the medicinal product for CAPs A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release B.II.b.3.z - Change in the manufacturing process of intermediate product - Other variation | 12/05/2017   | 31/05/2017   | SmPC, Annex II, Labelling and PL | the finished or               |